Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Elicera Therapeutics AB (publ) (ELIC.ST)
Gothenburg, SE
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.50% | +1.17% | -7.23% | -51.13% | -44.78% | -41.80% | -51.53% | -8.36% | -51.37% | -51.37% | -51.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-100.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+25.5% Q1'26: +54.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -4,681.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+52.7% Q1'26: +32.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
11.23M
est: 11.00M (+2.1%)
|
7.13M
est: 7.20M (-1.0%)
|
—
est: 2.90M (-100.0%)
|
12.05M
12.05M – 12.05M
+315.5% YoY
|
24.43M
24.40M – 24.47M
+102.8% YoY
|
97.30M
97.30M – 97.30M
+298.2% YoY
|
| EBITDA |
-17.09M
est: -6.60M (-158.9%)
|
-16.82M
est: -4.32M (-289.4%)
|
-17.40M
est: -1.74M (-899.9%)
|
-7.23M
-7.23M – -7.23M
-315.5% YoY
|
-14.66M
-14.68M – -14.64M
-102.8% YoY
|
-58.38M
-58.38M – -58.38M
-298.2% YoY
|
| EBIT |
-17.10M
est: -6.60M (-159.0%)
|
-16.88M
est: -4.32M (-290.8%)
|
-17.40M
est: -1.74M (-899.9%)
|
-7.23M
-7.23M – -7.23M
-315.5% YoY
|
-14.66M
-14.68M – -14.64M
-102.8% YoY
|
-58.38M
-58.38M – -58.38M
-298.2% YoY
|
| Net Income |
-16.40M
est: -46.02M (+64.4%)
|
-16.11M
est: -28.17M (+42.8%)
|
-17.41M
est: -18.78M (+7.3%)
|
-19.28M
-19.66M – -18.90M
-2.6% YoY
|
-14.46M
-21.31M – -7.61M
+25.0% YoY
|
53.01M
53.01M – 53.01M
+466.7% YoY
|
| SGA |
28.32M
est: 33.62B (-99.9%)
|
23.95M
est: 22.01B (-99.9%)
|
—
est: 8.86B (-100.0%)
|
36.83B
36.83B – 36.83B
+315.5% YoY
|
74.68B
74.57B – 74.78B
+102.8% YoY
|
297.38B
297.38B – 297.38B
+298.2% YoY
|
| EPS |
-0.83
est: -0.95 (+13.1%)
|
-0.51
est: -0.58 (+12.8%)
|
-0.38
est: -0.39 (+2.5%)
|
-0.40
-0.41 – -0.39
-2.6% YoY
|
-0.30
-0.44 – -0.16
+25.0% YoY
|
1.10
1.10 – 1.10
+466.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anna Koptina Gultekin | Head of Regulatory Affairs | — | female |
| Di Yu | Co-Founder, Acting Chief Scientific Officer & Chief Development Officer | — | male |
| Ingvar Karlsson | Chief Financial Officer | — | male |
| Jamal El-Mosleh | Chief Executive Officer & Co-Founder | — | male |
| Magnus Essand | Chief Science Officer, Co-Founder & Director (Leave of Absence) | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELIC.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
